Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a prodrug that, after intramuscular injection, is slowly hydrolyzed to testosterone. The released hormone binds to androgen receptors in target cells, influencing gene expression that regulates male sexual development, anabolic functions, and maintenance of secondary sexual characteristics.

The dosing regimen for Nebido is determined by the prescribing clinician based on the patient’s clinical status, testosterone levels, and response to therapy. Typically, the medication is administered by a healthcare professional as an intramuscular injection, and the exact schedule should follow the prescriber’s instructions.

Nebido is not indicated for use in women, and its safety in pregnancy or lactation has not been established. It is contraindicated for pregnant or nursing individuals, and women of childbearing potential should avoid exposure unless a clear medical need is established by a qualified physician.

To request Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Nebido provides a prolonged release of testosterone, typically requiring fewer injections (every 10–14 weeks) compared with shorter‑acting esters such as testosterone enanthate or cypionate, which often need weekly or bi‑weekly dosing. This reduced injection frequency can improve patient convenience, though individual response and side‑effect profiles may vary.

Nebido should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and discard any vial that shows signs of contamination or damage.

Nebido is given as an intramuscular injection, usually into the gluteal muscle, by a qualified healthcare professional. The injection is performed using aseptic technique, and the prescribed dosing interval is followed to maintain stable testosterone levels.

Serious risks associated with Nebido include polycythemia, which can increase the chance of blood clots, cardiovascular events such as myocardial infarction, worsening of prostate disease, severe hypertension, and rare allergic reactions. Regular monitoring of blood counts, prostate health, and cardiovascular status is essential.

Nebido is contraindicated in women, children, and men with known or suspected prostate cancer, severe untreated sleep apnea, uncontrolled heart failure, or a history of severe allergic reactions to testosterone undecanoate. Patients with significant cardiovascular disease should be evaluated carefully before initiating therapy.